Vol. 51, Issue 2, 1999April 01, 1999 EDT
Off-Label Use, Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative and Regulatory Policy
Off-Label Use, Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative and Regulatory Policy
Steven R. Salbu,
Articles in Vol. 51, Issue 2, 1999
Vol. 51, Issue 2, 1999
- Off-Label Use, Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative and Regulatory PolicySteven R. Salbu
- In Vento Scribere: The Intersection of Cyberspace and Patent LawMax Stul Oppenheimer
- The Elusive and Changing Definition of a Security: One Test Fits AllKyle M. Globerman
- Careful What You Wish For: The Tax Practitioner-Client Privilege Established by the Internal Revenue Service Restructuring and Reform Act of 1998Michael Wilson
- Tort Reform: A Call for Florida to Scale Back Its Independent Tort for the Spoilation of EvidenceStefan Rubin
- "Because I'm the Boss:" Employer Liability for Supervisors' Hostile Environment Sexual HarassmentGraham Penn
Steven R. Salbu, Off-Label Use, Prescription, and Marketing of FDA-Approved Drugs: An Assessment of Legislative and Regulatory Policy, 51 Fla. L. Rev. 181 (1999).